News & Events

FEATURED

Announcing Our $22 Million Series A to Accelerate AI in Precision Oncology

Co-led by DCVC and a16z, this funding will support the advancement of Vesta, world's first AI test to predict treatment response in bladder cancer, and catalyze expansion in other cancers.

Blog
May 2024
View Article
View Article

Upcoming Events

No items found.

Resources

All
Press Release
Paper
Abstract
Blog
Article

Valar Labs debuts AI-powered cancer care prediction tool and secures $22M

TechCrunch

May 2024

Valar Labs debuts AI-powered cancer care prediction tool and secures $22M

TechCrunch

May 2024

Valar Labs Announces $22 Million Series A to Advance Vesta, First AI Diagnostic Test to Predict Treatment Response in Bladder Cancer, and Catalyze Expansion in Other Cancers

Business Wire

May 2024

Valar Labs Announces $22 Million Series A to Advance Vesta, First AI Diagnostic Test to Predict Treatment Response in Bladder Cancer, and Catalyze Expansion in Other Cancers

Business Wire

May 2024

Announcing Our $22 Million Series A to Accelerate AI in Precision Oncology

Blog

May 2024

Announcing Our $22 Million Series A to Accelerate AI in Precision Oncology

Blog

May 2024

Valar Labs Announces Validation of First Histology-based Test to Predict Response to BCG in Bladder Cancer

Business Wire

May 2024

Valar Labs Announces Validation of First Histology-based Test to Predict Response to BCG in Bladder Cancer

Business Wire

May 2024

Development and Validation of Generalizable Interpretable AI Biomarker to Predict Clinical Outcomes in BCG-Treated Patients with Non-Muscle Invasive Bladder Cancer

Journal of Urology

May 2024

Development and Validation of Generalizable Interpretable AI Biomarker to Predict Clinical Outcomes in BCG-Treated Patients with Non-Muscle Invasive Bladder Cancer

Journal of Urology

May 2024

Predicting Response to Intravesical BCG in High Risk Non-Muscle Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12 Center Cohort

Journal of Urology

May 2024

Predicting Response to Intravesical BCG in High Risk Non-Muscle Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12 Center Cohort

Journal of Urology

May 2024

Prediction of recurrence and response to BCG with an artificial intelligence pathology platform in high risk non-muscle invasive bladder cancer

Society of Urologic Oncology

December 2023

Prediction of recurrence and response to BCG with an artificial intelligence pathology platform in high risk non-muscle invasive bladder cancer

Society of Urologic Oncology

December 2023

Complementary Pilot Analysis of Tumor Microenvironment and Nuclei in Recurrent vs. Non-recurrent Low-Grade Noninvasive Bladder Cancer Using Pathologic Review and Artificial Intelligence

Society of Urologic Oncology

December 2023

Complementary Pilot Analysis of Tumor Microenvironment and Nuclei in Recurrent vs. Non-recurrent Low-Grade Noninvasive Bladder Cancer Using Pathologic Review and Artificial Intelligence

Society of Urologic Oncology

December 2023

Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer

Cell Reports Medicine

April 2023

Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer

Cell Reports Medicine

April 2023

Development of artificial intelligence–derived histological biomarkers for first-line treatment selection in metastatic pancreatic ductal adenocarcinoma (mPDAC)

ASCO

January 2023

Development of artificial intelligence–derived histological biomarkers for first-line treatment selection in metastatic pancreatic ductal adenocarcinoma (mPDAC)

ASCO

January 2023

Predicting response to platinum-based chemotherapy for tubo-ovarian high-grade serous carcinoma using an artificial intelligence histopathology platform

International Journal of Gynecological Cancer

December 2022

Predicting response to platinum-based chemotherapy for tubo-ovarian high-grade serous carcinoma using an artificial intelligence histopathology platform

International Journal of Gynecological Cancer

December 2022

Assessing robustness of an artificial intelligence derived histological biomarker across different sites of disease and in serial sections in tubo-ovarian high-grade serous carcinoma

International Journal of Gynecological Cancer

December 2022

Assessing robustness of an artificial intelligence derived histological biomarker across different sites of disease and in serial sections in tubo-ovarian high-grade serous carcinoma

International Journal of Gynecological Cancer

December 2022

Valar Labs Announces $22 Million Series A to Advance Vesta, First AI Diagnostic Test to Predict Treatment Response in Bladder Cancer, and Catalyze Expansion in Other Cancers

Business Wire

May 2024

Valar Labs Announces $22 Million Series A to Advance Vesta, First AI Diagnostic Test to Predict Treatment Response in Bladder Cancer, and Catalyze Expansion in Other Cancers

Business Wire

May 2024

Valar Labs Announces Validation of First Histology-based Test to Predict Response to BCG in Bladder Cancer

Business Wire

May 2024

Valar Labs Announces Validation of First Histology-based Test to Predict Response to BCG in Bladder Cancer

Business Wire

May 2024

Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer

Cell Reports Medicine

April 2023

Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer

Cell Reports Medicine

April 2023

DLBCL-Morph: Morphological features computed using deep learning for an annotated digital DLBCL image set

Scientific Data | Nature

May 2021

DLBCL-Morph: Morphological features computed using deep learning for an annotated digital DLBCL image set

Scientific Data | Nature

May 2021

Development and Validation of Generalizable Interpretable AI Biomarker to Predict Clinical Outcomes in BCG-Treated Patients with Non-Muscle Invasive Bladder Cancer

Journal of Urology

May 2024

Development and Validation of Generalizable Interpretable AI Biomarker to Predict Clinical Outcomes in BCG-Treated Patients with Non-Muscle Invasive Bladder Cancer

Journal of Urology

May 2024

Predicting Response to Intravesical BCG in High Risk Non-Muscle Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12 Center Cohort

Journal of Urology

May 2024

Predicting Response to Intravesical BCG in High Risk Non-Muscle Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12 Center Cohort

Journal of Urology

May 2024

Prediction of recurrence and response to BCG with an artificial intelligence pathology platform in high risk non-muscle invasive bladder cancer

Society of Urologic Oncology

December 2023

Prediction of recurrence and response to BCG with an artificial intelligence pathology platform in high risk non-muscle invasive bladder cancer

Society of Urologic Oncology

December 2023

Complementary Pilot Analysis of Tumor Microenvironment and Nuclei in Recurrent vs. Non-recurrent Low-Grade Noninvasive Bladder Cancer Using Pathologic Review and Artificial Intelligence

Society of Urologic Oncology

December 2023

Complementary Pilot Analysis of Tumor Microenvironment and Nuclei in Recurrent vs. Non-recurrent Low-Grade Noninvasive Bladder Cancer Using Pathologic Review and Artificial Intelligence

Society of Urologic Oncology

December 2023

Development of artificial intelligence–derived histological biomarkers for first-line treatment selection in metastatic pancreatic ductal adenocarcinoma (mPDAC)

ASCO

January 2023

Development of artificial intelligence–derived histological biomarkers for first-line treatment selection in metastatic pancreatic ductal adenocarcinoma (mPDAC)

ASCO

January 2023

Predicting response to platinum-based chemotherapy for tubo-ovarian high-grade serous carcinoma using an artificial intelligence histopathology platform

International Journal of Gynecological Cancer

December 2022

Predicting response to platinum-based chemotherapy for tubo-ovarian high-grade serous carcinoma using an artificial intelligence histopathology platform

International Journal of Gynecological Cancer

December 2022

Assessing robustness of an artificial intelligence derived histological biomarker across different sites of disease and in serial sections in tubo-ovarian high-grade serous carcinoma

International Journal of Gynecological Cancer

December 2022

Assessing robustness of an artificial intelligence derived histological biomarker across different sites of disease and in serial sections in tubo-ovarian high-grade serous carcinoma

International Journal of Gynecological Cancer

December 2022

Prediction of neoadjuvant chemotherapy response in muscle-invasive bladder cancer: A machine learning approach

Annals of Oncology

September 2022

Prediction of neoadjuvant chemotherapy response in muscle-invasive bladder cancer: A machine learning approach

Annals of Oncology

September 2022

Validation of an artificial intelligence derived histological biomarker for gemcitabine response in resected pancreatic ductal adenocarcinoma (PDAC)

AACR

September 2022

Validation of an artificial intelligence derived histological biomarker for gemcitabine response in resected pancreatic ductal adenocarcinoma (PDAC)

AACR

September 2022

Gemcitabine response prediction in the adjuvant treatment of resected pancreatic ductal adenocarcinoma using an AI histopathology platform.

ASCO

January 2022

Gemcitabine response prediction in the adjuvant treatment of resected pancreatic ductal adenocarcinoma using an AI histopathology platform.

ASCO

January 2022

Announcing Our $22 Million Series A to Accelerate AI in Precision Oncology

Blog

May 2024

Announcing Our $22 Million Series A to Accelerate AI in Precision Oncology

Blog

May 2024

Valar Labs: Reimagining Cancer Treatment Decisions with Artificial Intelligence

March 2022

Valar Labs: Reimagining Cancer Treatment Decisions with Artificial Intelligence

March 2022

Valar Labs debuts AI-powered cancer care prediction tool and secures $22M

TechCrunch

May 2024

Valar Labs debuts AI-powered cancer care prediction tool and secures $22M

TechCrunch

May 2024

Valar Labs Using $4M in Seed Financing to Advance AI Tool for Personalizing Cancer Treatment

Precision Medicine Online

April 2022

Valar Labs Using $4M in Seed Financing to Advance AI Tool for Personalizing Cancer Treatment

Precision Medicine Online

April 2022